Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy
ContributorsCrea, Filippo
Published inEuropean heart journal, vol. 42, no. 31, p. 2973-2985
Publication date2021-08-17
Keywords
- Clopidogrel
- Humans
- Percutaneous Coronary Intervention
- Prasugrel Hydrochloride / therapeutic use
- Purinergic P2Y Receptor Antagonists
- Ticagrelor / therapeutic use
Affiliation
Citation (ISO format)
CREA, Filippo et al. Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. In: European heart journal, 2021, vol. 42, n° 31, p. 2973–2985. doi: 10.1093/eurheartj/ehab277
Main files (1)
Article (Published version)
Identifiers
- PID : unige:163453
- DOI : 10.1093/eurheartj/ehab277
- PMID : 34110420
ISSN of the journal0195-668X
